Botox Maker

[Nancie Fazzari]

Allerganplc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.[1][2][3] The company is the maker of Botox.[1]

Allergan's global headquarters are located in Dublin, Ireland. The company also maintains a significant presence in the United States, with administrative and operational headquarters located in various locations across the country, including Irvine, California and Madison, New Jersey.[9]

In 1948, pharmacist Gavin S. Herbert founded Allergan Pharmaceuticals, Inc.[10] In 1970, Allergan, Inc. became a public company via an initial public offering.[10] In 1977, Allergan announced plans to build a factory in Westport, Ireland.[11]

In 1980, it was acquired by SmithKline Corporation for $259 million[12] and was later spun-off by SmithKline Beecham in 1989.[13] In 1989, Allergan opened a manufacturing plant in Waco, Texas, to manufacture eye care products.[14]

In 1991, Allergan acquired the company Oculinum which manufactured products for eye muscle disorders.[15][16] Following the acquisition, the product was renamed Botox.[15][17] In 1996, Allergan received FDA approval for Alphagan ophthalmic solution for open-angle glaucoma and ocular hypertension.[18] In 1998, Allergan established The Allergan Foundation, a private US-based charitable foundation.[19]

In the spring of 1983, colleagues Allen Chao and David Hsia formed Watson Pharmaceuticals, a drug development in Libertyville, Illinois.[25] In late fall of 1983, the company moved to Corona, California, and began to develop and manufacture generic pharmaceuticals.[26] In February 1993, the company became a public company via an initial public offering.[26]

In 2015, Irish-based Actavis plc acquired U.S.-based Allergan, Inc., for $70 billion, and in effect redomiciled Allergan to Ireland in a corporate tax inversion.[4][33] Actavis CEO Brent Saunders became the CEO of the combined company.[34] In June 2015, the company took the Allergan name.[35]

On July 7, 2015, the company acquired the rights to the late stage CGRP migraine portfolio of Merck & Co, as well as two experimental drugs for an upfront payment of $250 million.[37] Later that summer, the company acquired Oculeve for $125 million[38] and Naurex for an upfront payment of $560 million.[39] In October 2015, the company acquired AqueSys, developer of ocular implants for an initial payment of $300 million,[40] along with Kythera Biopharmaceuticals, a company focused on the medical aesthetics market, for $2.1 billion.[41][42]

In late 2015, the company announced the acquisition of Northwood Medical Innovation, the developer of earFold.[43] On November 25, 2015, the company announced it would partner with Rugen Therapeutic to develop new therapies for autism spectrum disorder and obsessive compulsive disorder.[44]

On November 23, 2015, Allergan and Pfizer announced their intention to merge in a $160 billion transaction.[45] On April 5, 2016, after the Obama administration announced its plan to ban tax inversions, Pfizer terminated the acquisition and paid Allergan a $150 million breakup fee.[46][47]

In April 2016, the company announced it would partner with Heptares Therapeutics to develop a subtype-selective muscarinic agonists for Alzheimer's disease[48][49] and announced the acquisition of Topokine Therapeutics, gaining the phase IIb/III compound XAF5 - a treatment for dermatochalasis.[50]

In August 2016, Allergan plc sold its generic drugs business to Teva Pharmaceutical Industries in a $40.5 billion deal[51][52] and announced the acquisition of ForSight VISION5 for more than $95 million.[53]

In September 2016, CEO Saunders announced what he called a social contract to limit prices on the company's medications.[54][55] That same month, the company acquired RetroSense Therapeutics for more than $60 million,[56] announced the acquisition of Tobira Therapeutics for approximately $1.7 billion[57] and, a day later, the acquisition of Akarna Therapeutics for $50 million.[58]

In October 2016, the company sold Anda, its generic drug distribution business, to Teva for $500 million[59][60] and acquired Vitae Pharmaceuticals, focused on dermatology treatments, for $639 million.[59][61][62] That same month, the company announced it would acquire Motus Therapeutics, a developer of treatments for gastrointestinal disorders, for $200 million.[63] On November 22, 2016, the company acquired Chase Pharmaceuticals for $125 million.[64][65]

In 2017, the company acquired LifeCell, a specialist in regenerative medicine, for $2.9 billion and Zeltique Aesthetics, maker of CoolSculpting, for $2.4 billion.[66][67][68][69] On June 7, the company announced the acquisition of Keller Medical, a company that manufactures devices for use during breast augmentation surgery.[70] On December 12, the company announced the acquisition of Repros Therapeutics, a developer of drugs for reproductive system diseases.[71]

In 2018, along with several other drug manufacturers and distributors, the company was sued by several municipalities and states in the U.S. due to the manufacture of opioids, which have been abused in what has been referred to as the opioid epidemic.[76][77]

In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion,[7] which would return Allergan to the U.S. for tax purposes.[8] On the announcement of the transaction, Abbvie disclosed that its 2019 net effective tax rate was 9%, but that post the acquisition, the Group's effective tax rate would rise to 13%. The merger was expected to close in 2020.[8]

Allergan acquires, develops, manufactures and markets branded products in four therapeutic areas: medical aesthetics, eye care, central nervous system, and gastroenterology. The company manufactures several pharmaceutical products including Botox (botulinum toxin), Juvederm (injectable filler), CoolSculpting (cryolipolysis), Alphagan (brimonidine), Vraylar (cariprazine HCI), Linzess (linaclotide),[1] and Ubrelvy (ubrogepant).[15][20][66][18][78]

Botox maker AbbVie, a global pharmaceutical company, said in a statement on its website that it has temporarily suspended operations for its aesthetics products, including Botox, in Russia while the crisis in Ukraine unfolds. The company does not operate manufacturing plants in the region, according to the statement. AbbVie will continue to produce and distribute essential and life-saving medicines to patients in Russia.

"As a global biopharmaceutical company, we have a responsibility to patients who depend on our medicines," AbbVie said, which also reiterated its commitment to providing clinical trial participants with experimental drugs. "Our priority is to ensure the safety of our colleagues and help patients get the medicines they need."

Amid intense public pressure on western companies to halt their activities in Russia, drugmakers are having to walk a fine line between boycotting the country and continuing to supply ordinary citizens with critical medications and pharmaceutical devices. Abbott, which has publicly condemned the war, said this week it was suspending non-essential business in Russia, including new investments, business development and advertising. But the company said it is continuing to provide life-sustaining medicines for cancer maintenance and organ function in Russia.

Other pharmaceutical companies such as Germany's Bayer, Eli Lilly and Pfizer, have taken similar stances. They are suspending non-essential operations in Russia while continuing to supply vital medicines and devices.

Withholding life-saving medical treatments from people would cross an ethical line, she emphasized. "If we're looking at it based on someone's right to life and health, then suspending something like Botox is obviously inconvenient for some folks, but it does not affect life in terms of livability. But if the decision were made to cut off all supply chains for all sorts of medication and biomedical supplies and drugs, that would be tragic."

"Denying Russian children and adults of essential medications would be cruel and insupportable," he said. But, "it makes sense to curtail business operations in Russia" by moving manufacturing plants and clinical trials elsewhere, for example, to "insure that any profitable joint ventures are either discontinued or that any profits go to provide needed humanitarian support for Ukrainians," Magnus said.

The drugmaker AbbVie, owner of the top-selling drug Humira, announced on Tuesday, June 25, it will buy Allergan for $63 billion, which makes this the second-biggest takeover in the pharmaceutical industry this year!

Allergan is the parent company of some of the most popular cosmetic injections and devices on the market, including Juvederm, CoolSculpting and Botox, the drug used to treat muscle spasms, migraines and skin wrinkles.

Using magnetic muscle stimulation (MMS), CoolTone technology penetrates the underlying muscle layers and induces involuntary muscle contractions to strengthen muscle fibers, resulting in improved muscle conditioning.

What does this mean for you? As the medical aesthetics industry continues to grow and new technologies hit the marketplace, more businesses are looking to hire individuals who can perform these cosmetic treatments.

Since treatments like Botox and CoolSculpting are considered cosmetic, medical aesthetics training is a must! With over 15 years of excellence, National Laser Institute offers medical aesthetics courses for those interested in jumpstarting an exciting career in this multi-billion-dollar marketplace. Whether you are looking to become a cosmetic laser technician or a cosmetic injector, medical aesthetics courses have several benefits:

Are you looking for a new and exciting career opportunity? How about a way to supercharge your earning potential? National Laser Institute offers medical aesthetics training for those looking to jumpstart a new career in the health and beauty marketplace!

3a8082e126